Cargando…

In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model

Background: Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. In vitro models allow for extensive profiling of drug clearance using a wide array o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vossen, M G, Pferschy, S, Milacek, C, Haidinger, M, Karolyi, Mario, Vass, Zoltan, Burgmann, Heinz, Maier-Salamon, Alexandra, Wicha, S G, Jäger, W, Zeitlinger, M, Stimpfl, T, Wittek, T, Thalhammer, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264131/
https://www.ncbi.nlm.nih.gov/pubmed/34248646
http://dx.doi.org/10.3389/fphar.2021.702455
_version_ 1783719484163358720
author Vossen, M G
Pferschy, S
Milacek, C
Haidinger, M
Karolyi, Mario
Vass, Zoltan
Burgmann, Heinz
Maier-Salamon, Alexandra
Wicha, S G
Jäger, W
Zeitlinger, M
Stimpfl, T
Wittek, T
Thalhammer, F
author_facet Vossen, M G
Pferschy, S
Milacek, C
Haidinger, M
Karolyi, Mario
Vass, Zoltan
Burgmann, Heinz
Maier-Salamon, Alexandra
Wicha, S G
Jäger, W
Zeitlinger, M
Stimpfl, T
Wittek, T
Thalhammer, F
author_sort Vossen, M G
collection PubMed
description Background: Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. In vitro models allow for extensive profiling of drug clearance using a wide array of hemofilters and flow rates. We present a bovine blood based in vitro pharmacokinetic model for intermittent renal replacement therapy. Methods: Four different drugs were analyzed: gentamicin, doripenem, vancomicin and teicoplanin. The investigated drug was added to a bovine blood reservoir connected to a hemodialysis circuit. In total seven hemofilter models were analyzed using commonly employed flow rates. Pre-filter, post-filter and dialysate samples were drawn, plasmaseparated and analyzed using turbidimetric assays or HPLC. Protein binding of doripenem and vancomycin was measured in bovine plasma and compared to previously published values for human plasma. Results: Clearance values were heavily impacted by choice of membrane material and surface as well as by dialysis parameters such as blood flow rate. Gentamicin clearance ranged from a minimum of 90.12 ml/min in a Baxter CAHP-170 diacetate hemofilter up to a maximum of 187.90 ml/min in a Fresenius medical company Fx80 polysulfone model (blood flow rate 400 ml/min, dialysate flow rate 800 ml/min). Clearance of Gentamicin vs Vancomicin over the F80s hemofilter model using the same flow rates was 137.62 mL vs 103.25 ml/min. Doripenem clearance with the Fx80 was 141.25 ml/min. Conclusion: Clearance values corresponded very well to previously published data from clinical pharmacokinetic trials. In conjunction with in silico pharmacometric models. This model will allow precise dosing recommendations without the need of large scale clinical trials.
format Online
Article
Text
id pubmed-8264131
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82641312021-07-09 In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model Vossen, M G Pferschy, S Milacek, C Haidinger, M Karolyi, Mario Vass, Zoltan Burgmann, Heinz Maier-Salamon, Alexandra Wicha, S G Jäger, W Zeitlinger, M Stimpfl, T Wittek, T Thalhammer, F Front Pharmacol Pharmacology Background: Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. In vitro models allow for extensive profiling of drug clearance using a wide array of hemofilters and flow rates. We present a bovine blood based in vitro pharmacokinetic model for intermittent renal replacement therapy. Methods: Four different drugs were analyzed: gentamicin, doripenem, vancomicin and teicoplanin. The investigated drug was added to a bovine blood reservoir connected to a hemodialysis circuit. In total seven hemofilter models were analyzed using commonly employed flow rates. Pre-filter, post-filter and dialysate samples were drawn, plasmaseparated and analyzed using turbidimetric assays or HPLC. Protein binding of doripenem and vancomycin was measured in bovine plasma and compared to previously published values for human plasma. Results: Clearance values were heavily impacted by choice of membrane material and surface as well as by dialysis parameters such as blood flow rate. Gentamicin clearance ranged from a minimum of 90.12 ml/min in a Baxter CAHP-170 diacetate hemofilter up to a maximum of 187.90 ml/min in a Fresenius medical company Fx80 polysulfone model (blood flow rate 400 ml/min, dialysate flow rate 800 ml/min). Clearance of Gentamicin vs Vancomicin over the F80s hemofilter model using the same flow rates was 137.62 mL vs 103.25 ml/min. Doripenem clearance with the Fx80 was 141.25 ml/min. Conclusion: Clearance values corresponded very well to previously published data from clinical pharmacokinetic trials. In conjunction with in silico pharmacometric models. This model will allow precise dosing recommendations without the need of large scale clinical trials. Frontiers Media S.A. 2021-06-24 /pmc/articles/PMC8264131/ /pubmed/34248646 http://dx.doi.org/10.3389/fphar.2021.702455 Text en Copyright © 2021 Vossen, Pferschy, Milacek, Haidinger, Karolyi, Vass, Burgmann, Maier-Salamon, Wicha, Jäger, Zeitlinger, Stimpfl, Wittek and Thalhammer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Vossen, M G
Pferschy, S
Milacek, C
Haidinger, M
Karolyi, Mario
Vass, Zoltan
Burgmann, Heinz
Maier-Salamon, Alexandra
Wicha, S G
Jäger, W
Zeitlinger, M
Stimpfl, T
Wittek, T
Thalhammer, F
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
title In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
title_full In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
title_fullStr In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
title_full_unstemmed In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
title_short In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
title_sort in vivo / in vitro correlation of pharmacokinetics of gentamicin, vancomycin, teicoplanin and doripenem in a bovine blood hemodialysis model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264131/
https://www.ncbi.nlm.nih.gov/pubmed/34248646
http://dx.doi.org/10.3389/fphar.2021.702455
work_keys_str_mv AT vossenmg invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT pferschys invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT milacekc invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT haidingerm invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT karolyimario invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT vasszoltan invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT burgmannheinz invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT maiersalamonalexandra invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT wichasg invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT jagerw invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT zeitlingerm invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT stimpflt invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT wittekt invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel
AT thalhammerf invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel